Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages 5368-5376

  Yuan, Ray Hwang ^a,c   Jeng, Yung Ming ^a,b   Pan, Hung Wei ^b   Hu, Fu Chang ^a,b   Lai, Po Lin ^a   Lee, Po Huang ^a,c   Hsu, Hey Chi ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; MESSENGER RNA; PROTEIN KIAA0101; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE; P53 GENE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SURVIVAL RATE; TUMOR CELL; TUMOR RECURRENCE; TUMOR THROMBUS;

ADULT; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 34848837730     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1113     Document Type: Article

References (45)

1. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35:S72-8.
2. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 2002;32:S66-81.
3. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-19.
4. Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003;98:119-27.
5. Hu RH, Lee PH, Yu SC, et al. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 1996;120:23-9.
6. Poon RT, Fan ST, Ng I O, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-7.
7. Moradpour D, Wands JR. The molecular pathogenesis of hepatocellular carcinoma. J Viral Hepat 1994;1:17-31.
8. Tabor E. Tumor suppress or genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 1994;42:357-65.
9. Hui AM, Makuuchi M, Li X. Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology 1998;45:1635-42.
10. Jonsson ZO, Hindges R, Hübscher U. Regulation of DNA replication and repair proteins through interaction with the front side of proliferating cell nuclear antigen. EMBO J 1998;17:2412-25.
11. Warbrick E. The puzzle of PCNA's many partners. Bioessays 2000;22:997-1006.
12. Warbrick E. A functional analysis of PCNA-binding peptides derived from protein sequence, interaction screening and rational design. Oncogene 2006;25:2850-9.
13. Yu P, Huang B, Shen M, et al. p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. Oncogene 2001;20:484-9.
14. Mizutani K, Onda M, Asaka S, et al. Overexpressed in anaplastic thyroid carcinoma-1 (OEATC-1) as a novel gene responsible for anaplastic thyroid carcinoma. Cancer 2005;103:1785-90.
15. Petroziello J, Yamane A, Westendorf L, et al. Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer. Oncogene 2004;23:7734-45.
16. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
17. Watanabe H, Pan ZQ, Schreiber-Agus N, DePinho RA, Hurwitz J, Xiong Y. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci U S A 1998;95:1392-7.
18. Scott M, Bonnefin P, Vieyra D, et al. UV-induced binding of ING1 to PCNA regulates the induction of apoptosis. J Cell Sci 2001;114:3455-62.
19. Kelman Z, O'Donnell M. Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps. Nucleic Acids Res 1995;23:3613-20.
20. Kelman Z, Hurwitz J. Protein-PCNA interactions: a DNA-scanning mechanism? Trends Biochem Sci 1998;23:236-8.
21. Osada S, Saji S, Kuno T. Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J Surg Oncol 2004;85:48-54.
22. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995;375:159-61.
23. Nakanishi M, Robetorye RS, Pereira-Smith OM, Smith JR. The C-terminal region of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. J Biol Chem 1995;270:17060-3.
24. Boulaire J, Fotedar A, Fotedar R. The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris) 2000;48:190-202.
25. Simpson F, Lammerts vBK, Butterfield N, et al. The PCNA-associated factor KIAA0101/p15(PAF) binds the potential tumor suppressor product p33ING1b. Exp Cell Res 2006;312:73-85.
26. Li R, Hannon GJ, Beach D, Stillman B. Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol 1996;6:189-99.
27. Nagase T, Miyajima N, Tanaka A, et al. Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res 1995;2:37-43.
28. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001;61:3124-30.
29. Peng SY, Lai PL, Chu JS, et al. Expression and hypomethylation of α-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology 1993;17:35-41.
30. Hsu HC, Chiou TJ, Chen JY, Lee CS, Lee PH, Peng SY. Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology 1991;13:923-8.
31. Yuan RH, Jeng YM, Chen HL, et al. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage HCC, β-catenin mutation, and favorable prognosis. Clin Cancer Res 2005;11:2568-75.
32. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin mutations. Int J Cancer 2004;112:44-50.
33. Hsu HC, Wu TT, Wu MZ, Sheu JC, Lee CS, Chen DS. Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. Cancer 1988;61:2095-9.
34. Vincent S, Marty L, Fort P. S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eucaryotic cells and tissues. Nucleic Acids Res 1993;21:1498.
35. Liu SH, Lin CY, Peng SY, et al. Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol 2002;160:1831-7.
36. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 1993;53:4691-4.
37. Hsu HC, Peng SY, Lai PL, Chu JS, Lee PH. Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis. Int J Oncol 1994;4:1341-7.
38. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York (NY): John Wiley & Sons; 2000.
39. Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York (NY): John Wiley & Sons; 1999.
40. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003;116:3051-60.
41. Guo M, Li J, Wan D, Gu J. KIAA0101 (OEACT-1), an expressionally down-regulated and growth-inhibitory gene in human hepatocellular carcinoma. BMC Cancer 2006;6:109-17.
42. Sheen IS, Jeng KS, Wu JY. Is p53 gene mutation an indicator of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol 2003;9:1202-7.
43. Peng SY, Ou YH, Chen WJ, et al. Aberrant expressions of annexin A10 short isoform, osteopontin and a-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol 2005;26:1053-61.
44. Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006;209:549-58.
45. Pan HW, Chou HY, Liu SH, Peng SY, Liu CL, Hsu HC. Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle 2006;5:2676-87.